[go: up one dir, main page]

MX2018010387A - Preparacion que contiene esomeprazol. - Google Patents

Preparacion que contiene esomeprazol.

Info

Publication number
MX2018010387A
MX2018010387A MX2018010387A MX2018010387A MX2018010387A MX 2018010387 A MX2018010387 A MX 2018010387A MX 2018010387 A MX2018010387 A MX 2018010387A MX 2018010387 A MX2018010387 A MX 2018010387A MX 2018010387 A MX2018010387 A MX 2018010387A
Authority
MX
Mexico
Prior art keywords
preparation containing
esomeprazole
containing esomeprazole
active ingredient
present
Prior art date
Application number
MX2018010387A
Other languages
English (en)
Inventor
Ju Kim Jung
Mo Kuk Yun
Min Son Hyung
Original Assignee
Yoo Young Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoo Young Pharm Co Ltd filed Critical Yoo Young Pharm Co Ltd
Publication of MX2018010387A publication Critical patent/MX2018010387A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una preparación que contiene esomeprazol como un ingrediente activo. La presente invención se caracteriza porque un sistema de liberación controlada se introduce de tal manera que la eficacia de esomeprazol, que es un ingrediente activo, se puede exhibir continuamente.
MX2018010387A 2016-02-29 2017-01-17 Preparacion que contiene esomeprazol. MX2018010387A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160024669A KR101884230B1 (ko) 2016-02-29 2016-02-29 에소메프라졸을 포함하는 제제
PCT/KR2017/000550 WO2017150803A1 (ko) 2016-02-29 2017-01-17 에소메프라졸을 포함하는 제제

Publications (1)

Publication Number Publication Date
MX2018010387A true MX2018010387A (es) 2018-11-29

Family

ID=59744180

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010387A MX2018010387A (es) 2016-02-29 2017-01-17 Preparacion que contiene esomeprazol.

Country Status (11)

Country Link
US (1) US20190046459A1 (es)
EP (1) EP3424496A4 (es)
JP (1) JP2019507158A (es)
KR (1) KR101884230B1 (es)
CN (1) CN108697648A (es)
AU (1) AU2017226585A1 (es)
BR (1) BR112018017214A2 (es)
CA (1) CA3014864C (es)
MX (1) MX2018010387A (es)
RU (1) RU2018134035A (es)
WO (1) WO2017150803A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
CN111991367A (zh) * 2020-09-21 2020-11-27 青岛吉达巴尔国际贸易有限公司 一种埃索美拉唑镁脉冲微丸胶囊剂及制备方法
KR20220091629A (ko) 2020-12-23 2022-07-01 (주)휴온스 안정성이 증가된 에스오메프라졸 함유 장용성 코팅 정제 및 이의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
AU3193200A (en) * 1999-03-19 2000-10-09 Kyowa Hakko Kogyo Co. Ltd. Tablets and process for producing the same
US8206741B2 (en) * 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
WO2005027880A1 (en) * 2003-09-25 2005-03-31 Natco Pharma Limited Enteric soft gelatin capsule containing esomeprazole and method of preparation
AR051654A1 (es) * 2004-11-04 2007-01-31 Astrazeneca Ab Nuevas formulaciones de pellets de liberacion modificada para inhibidores de la bomba de protones
MX2010001071A (es) * 2007-07-27 2010-03-09 Depomed Inc Formas de dosificacion retentivas gastricas pulsatiles.
US20090228941A1 (en) * 2008-03-05 2009-09-10 At&T Intellectual Property, Lp Video System and a Method of Using the Video System
CN102209529A (zh) * 2008-09-09 2011-10-05 阿斯利康(瑞典)有限公司 将药物组合物递送至有需要的患者的方法
US20110177164A1 (en) * 2008-10-06 2011-07-21 Gopal Rajan Pharmaceutical Compositions Comprising Amorphous Esomeprazole, Dosage Forms And Process Thereof
CA2757979A1 (en) * 2009-04-09 2010-10-14 Alkermes Pharma Ireland Limited Controlled-release clozapine compositions
US20110293713A1 (en) * 2010-06-01 2011-12-01 Snehalatha Movva Pharmaceutical formulations comprising nsaid and proton pump inhibitor drugs
KR102060738B1 (ko) * 2012-12-13 2019-12-30 한미약품 주식회사 에스오메프라졸 유리염기 또는 그의 알칼리염을 포함하는 고미가 차폐된 약학 제제 및 이의 제조방법
CA2900763C (en) * 2013-02-13 2021-04-06 Reza Fathi Pharmaceutical compositions for the treatment of helicobacter pylori

Also Published As

Publication number Publication date
RU2018134035A3 (es) 2020-04-23
JP2019507158A (ja) 2019-03-14
CA3014864A1 (en) 2017-09-08
US20190046459A1 (en) 2019-02-14
KR20170101721A (ko) 2017-09-06
EP3424496A1 (en) 2019-01-09
BR112018017214A2 (pt) 2019-01-02
AU2017226585A1 (en) 2018-10-04
WO2017150803A1 (ko) 2017-09-08
CA3014864C (en) 2021-01-12
RU2018134035A (ru) 2020-04-01
EP3424496A4 (en) 2020-01-15
CN108697648A (zh) 2018-10-23
KR101884230B1 (ko) 2018-08-01

Similar Documents

Publication Publication Date Title
ZA202004557B (en) Modulatory polynucleotides
MX2023010042A (es) Polinucleotidos moduladores.
ZA201708692B (en) Antibacterial compounds
MX2020003825A (es) Formas de dosificacion solidas de palbociclib.
MY192588A (en) Pharmaceutical compounds
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
GB2541571A (en) Pharmaceutical compositions
MX2021011906A (es) Composiciones de liberacion retardada de linaclotida.
PH12016501841A1 (en) Immunosuppressant formulation
PH12016502002B1 (en) Novel bacteriophage and composition comprising same
EA201791009A1 (ru) Композиции, содержащие циклоспорин
IL262059A (en) A layer coated tablet with high chemical stability of the active ingredient
IN2014CH00840A (es)
MX368268B (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
PH12016502544B1 (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
MX2018010387A (es) Preparacion que contiene esomeprazol.
SG11201608845PA (en) Cosmetic composition containing mentha haplocalyx as active ingredient
PH12019500024A1 (en) Pharmaceutical compositions
NZ721832A (en) Solid forms of tenofovir
PH12018500579A1 (en) Fungal keratitis prophylactic or therapeutic agent
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
PH12018501166B1 (en) Concentrated gibberellin solution formulations
PH12015000067A1 (en) Ulasimang bato(peperomia pellucida) tablet as anti-hyperuricemic agent